Relapse of primary bone lymphoma: what is the therapy?
Primary bone lymphoma is a rare disease. We report the rare case of relapsed indolent primary bone Lymphoma (PBL), which was effectively treated using Bendamustine and Rituximab. A male 78-years-old patient presented with a painful mass in the left arm associated to enlargement of lymph nodes in axi...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2014-08-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://mjhid.org/index.php/mjhid/article/view/1908 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Primary bone lymphoma is a rare disease. We report the rare case of relapsed indolent primary bone Lymphoma (PBL), which was effectively treated using Bendamustine and Rituximab. A male 78-years-old patient presented with a painful mass in the left arm associated to enlargement of lymph nodes in axillary region. The ultrasonography scan showed a patchy and hypoechoic area in the biceps that was 100x35mm, confirmed by CT scan. Indeed a whole body CT scan found pathological adenopathies in ipsilateral axillary region.The histological examination and immunohistochemical staining of the bone biopsy confirmed a diagnosis of B small cell Lymphocytic Lymphoma, clinical stage IVA (according to the Ann Arbor Staging Classification for Lymphomas). Recommended treatments for PBL were used according to the guidelines , but relapses after an initial complete response occurred. Once options recommended were exhausted, we decided to use a histology-driven approaches such as for the others NHL. According to Rummel experience, we decide to treat our patient with Bendamustin 90 mg/mq gg1-2 q28 plus Rituximab 375 mg/mq q28 (BR). Based on our experience, BR combination could be considered a good option for PBL relapsed with indolent subtype. |
|---|---|
| ISSN: | 2035-3006 |